Table 1.

Intervention and assessment schedule for the INP trial

Execute project	W-4–W0	W1	W2	W3	W4	W5	W6	W8	W10	W12	W20	W24	W36	W48
	Screening period
Sequencing/neoantigen preparation	√
Neoantigen immunisation		√√	√	√	√					√	√
Physical examination	√	√	√	√	√	√	√	√	√	√	√	√	√	√
Laboratory examination	√*				√			√		√	√	√	√	√
CT/MRI	√*							√		√		√	√	√
ctDNA detection	√*				√			√		√		√	√	√
IFN-γ, CD4 +T cells, CD8 +T cells	√*				√						√			√
AEs (CTCAE)	√*	√	√	√	√	√	√	√	√	√	√	√	√	√
QLQ (EORTC QLQ-C30)	√*				√			√		√		√		√
Survival follow-up		√	√	√	√	√	√	√	√	√	√	√	√	√

√√ Twice a week.

*Need to screen out qualified neoantigens before relevant testing.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; ctDNA, circulating tumour DNA; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; INP, Individualized neoantigen tumor peptides.